Table 1.
Baseline characteristics of the 738 patients initially treated with upfront SRS alone.
| n (%/IQR) | |
|---|---|
| Total | 738 |
| Age, y, median | 62 (53–70) |
| Sex | |
| Female | 342 (46.3) |
| Male | 396 (53.7) |
| Ethnicity | |
| Caucasian | 654 (88.6) |
| African American | 72 (9.8) |
| Hispanic | 8 (1.1) |
| Other | 4 (0.5) |
| Primary Site | |
| Breast | 102 (13.8) |
| HER2 + | 46 (45.1) |
| HER2 - | 45 (44.1) |
| HER2 unknown | 11 (10.8) |
| Gastrointestinal | 61 (8.3) |
| Lung | 364 (49.3) |
| Adenocarcinoma | 216 (59.3) |
| Squamous cell carcinoma | 57 (15.7) |
| Other | 91 (25.0) |
| Melanoma | 117 (15.9) |
| BRAF + | 11 (9.4) |
| BRAF - | 11 (9.4) |
| BRAF unknown | 95 (81.2) |
| RCC | 68 (9.2) |
| Other | 26 (3.5) |
| Number of brain metastases | |
| 1 | 373 (50.5) |
| 2 | 170 (23.0) |
| 3 | 94 (12.7) |
| 4+ | 101 (13.7) |
| Presence of brainstem metastasis | 23 (3.1) |
| Extent of systemic disease | |
| None | 115 (15.6) |
| Oligometastasis | 254 (34.4) |
| Widespread metastasis | 224 (30.3) |
| Unknown | 37 (5.0) |
| Systemic disease status | |
| Stable | 399 (54.1) |
| Progressive | 264 (35.8) |
| Unknown | 74 (10.0) |
| KPS | |
| ≤ 70% | 183 (24.8) |
| 80% | 320 (43.4) |
| 90%–100% | 234 (31.8) |
| DS-GPA | |
| 0–1 | 159 (22.3) |
| 1.5–2 | 293 (41.0) |
| 2.5–3 | 218 (30.5) |
| >3 | 44 (6.2) |
| Lowest SRS dose, median | 19.0 (17.0–21.0) |
Abbreviations: DS-GPA, diagnosis-specific graded prognostic assessment; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; KPS, Karnofsky performance status; RCC, renal cell carcinoma; SRS,stereotactic radiosurgery.